Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia (ITP)

This study has been completed.
National Natural Science Foundation of China
Information provided by (Responsible Party):
Renchi Yang, Institute of Hematology & Blood Diseases Hospital Identifier:
First received: October 26, 2012
Last updated: May 15, 2017
Last verified: May 2017
A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this study is to compare the efficacy and tolerability of two different regimens of low doses rituximab for the treatment of adult patients with ITP.

Condition Intervention
Immune Thrombocytopenic Purpura
Drug: Rituximab

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Prospective Multi-center Randomized Controlled Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia

Resource links provided by NLM:

Further study details as provided by Institute of Hematology & Blood Diseases Hospital:

Primary Outcome Measures:
  • Compare the platelet count between two groups given different doses of Rituximab. [ Time Frame: Patients will be followed for 6 months after Rituximab treatment. ]

Enrollment: 100
Study Start Date: August 2012
Study Completion Date: February 2016
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rituximab A group
375mg/m2 for once
Drug: Rituximab
Other Name: Trade names Rituxan and MabThera
Active Comparator: Rituximab B group
100mg/week for four weeks
Drug: Rituximab
Other Name: Trade names Rituxan and MabThera

Detailed Description:
Hundreds of Patients without infection (age 18 to 60 years old) developed Chronic ITP. All patients will be enrolled in this study and will be randomly assigned to receive 100 mg rituximab weekly for 4 weeks (group A) or a single dose of 375 mg/m2 rituximab (group B). After treatment all patients will be followed for two years. During observation platelet count and B lymphocyte will be detected every month.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult chronic ITP, age 18 to 60

Exclusion Criteria:

  • pregnant woman with ITP; liver disease and kidney disease; allergy to rituximab
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01719692

China, Tianjin
Hospital of Blood disease
Tianjin, Tianjin, China, 300020
Sponsors and Collaborators
Institute of Hematology & Blood Diseases Hospital
National Natural Science Foundation of China
Principal Investigator: RENCHI YANG, Dr Hospital of Blood disease
  More Information

Responsible Party: Renchi Yang, Thrombosis and Hemostasis Center, Institute of Hematology & Blood Diseases Hospital Identifier: NCT01719692     History of Changes
Other Study ID Numbers: low dose rituximab for ITP
Study First Received: October 26, 2012
Last Updated: May 15, 2017

Additional relevant MeSH terms:
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Blood Coagulation Disorders
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Immune System Diseases
Hemorrhagic Disorders
Autoimmune Diseases
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents processed this record on May 23, 2017